Hematologic Diagnosis Specialist in Guatemala City
Catch the problem before it becomes a problem. That changes everything.
Some hematologic diseases have prior states that are detectable — and treatable — before they become leukemia, lymphoma, or myeloma. Identifying them in time is the difference between watchful surveillance and an advanced cancer diagnosis.
When should you consult Dr. Valvert?
You were found to have monoclonal protein in blood or urine and don't know what it means
You have a family history of leukemia, lymphoma, or multiple myeloma
Your doctor found abnormalities in your blood count with no clear explanation
You were diagnosed with MGUS or smoldering myeloma and don't have specialized follow-up
You have persistent mild cytopenias with no identified cause
You were exposed to toxins or prior radiotherapy that increases hematologic risk
⚡ Consultations Monday to Saturday | In person and telehealth available
1%
annual risk of MGUS progressing to multiple myeloma — detectable with active surveillance
5-10 years
average time between the first abnormal finding and a leukemia diagnosis in some cases
90%+
remission rate in leukemia when treated at an early stage with the correct protocol
Q475
initial consultation with complete hematologic risk evaluation
Active surveillance before the problem becomes urgent.
With over 10 international scientific publications and a fellowship in flow cytometry, I design follow-up plans for MGUS, myelodysplastic syndromes, and pre-malignant states — with clear criteria for when to observe and when to intervene.
Not every hematologic abnormality is cancer — but some can be.
There are hematologic conditions that sit between normal and malignant: so-called pre-malignant or precursor states. Some progress slowly over years. Others never progress. Knowing which category a patient falls into determines whether to observe, treat, or simply reassure.
Monoclonal gammopathy of uncertain significance (MGUS) can precede multiple myeloma by years. Low-risk myelodysplastic syndromes can progress to acute myeloid leukemia. Clonal hematopoiesis of indeterminate potential (CHIP) increases the risk of malignant hematologic and cardiovascular disease. None of these conditions always requires treatment — but all require specialized follow-up with clear criteria for when to act.
“Detecting myeloma while it's still MGUS, or leukemia while it's still a low-risk myelodysplastic syndrome, completely changes the prognosis. Active surveillance is not passive observation: it's knowing exactly what to look for and when to intervene.”—Dra. Fabiola Valvert
Findings that deserve specialized hematologic evaluation.
Many pre-malignant states are detected as incidental findings on routine exams — without symptoms. Others present with subtle signs that go unnoticed. Recognizing them is the first step.
Monoclonal protein in blood or urine
An M spike found on protein electrophoresis or Bence-Jones protein in urine. May indicate MGUS, smoldering myeloma, or multiple myeloma — requires a complete hematologic evaluation to classify correctly.
Persistent mild cytopenias
Mild anemia, leukopenia, or thrombocytopenia that persists over time with no evident cause. May be the first sign of a myelodysplastic syndrome or early marrow infiltration.
Persistent lymphocytosis
Sustained increase in lymphocytes on the blood count with no infection to explain it. May indicate monoclonal B-cell lymphocytosis (MBL), a precursor of chronic lymphocytic leukemia in a subgroup of patients.
Chronic neutropenia
A persistently low neutrophil count. May be benign and idiopathic, or it may be the initial manifestation of a myelodysplastic syndrome — distinguishing between them requires specialized evaluation.
Family history of hematologic cancer
First-degree relatives with leukemia, lymphoma, or multiple myeloma. Some forms of leukemia and lymphoma have a hereditary component that increases the risk within a family.
Exposure to toxins or prior chemotherapy
Occupational exposure to benzene, ionizing radiation, or prior treatment with chemotherapy increases the risk of secondary hematologic malignancies — especially myelodysplastic syndromes and acute myeloid leukemia.
Splenomegaly with no apparent cause
An enlarged spleen detected on ultrasound or physical exam with no infection or liver disease to explain it. May be the first manifestation of lymphoma, chronic leukemia, or a storage disease.
Abnormalities in a prior bone marrow biopsy
Findings on a bone marrow biopsy performed for another reason — cellular dysplasia, increased blasts, infiltration — that require follow-up by a hematology specialist.
Do you identify with any of these?
A one-hour first consultation is enough to begin the workup and, if applicable, reach a clear diagnosis
Follow-up that detects change before it becomes urgent.
Active surveillance in hematology is not passive waiting. It is a structured protocol with defined intervals, specific studies, and clear criteria for when to shift from observation to treatment. Dr. Valvert designs the follow-up plan according to each patient's individual risk.
MGUS and smoldering multiple myeloma
Low-risk MGUS requires monitoring every 6 to 12 months. High-risk MGUS and smoldering myeloma require more frequent monitoring — every 3 to 6 months — with defined progression criteria. Early detection of progression allows treatment to begin before organ damage occurs.
Low-risk myelodysplastic syndromes
Low-risk myelodysplastic syndromes (very low, low, and intermediate IPSS-R) can be followed with active surveillance for months or years. Progression to high risk or transformation to acute leukemia are the events that trigger treatment — and they must be detected in time.
Monoclonal B-cell lymphocytosis
Monoclonal B-cell lymphocytosis (MBL) is a precursor state of chronic lymphocytic leukemia. Most never progress, but a subgroup does. Follow-up with periodic immunophenotyping allows progression to be detected while it is still at an early stage.
“MGUS doesn't need treatment. Myeloma does. The difference between the two is sometimes a protein that rises more than expected between two checkups. That's why active follow-up isn't optional — it's part of the treatment.”—Dra. Fabiola Valvert
How hematologic risk is evaluated in consultation
Hematologic risk evaluation begins with a complete medical history and the available studies. In the first consultation with Dr. Valvert, risk is classified, a differential diagnosis is established, and a surveillance plan is designed.
Medical history and risk factors
Family history of hematologic diseases, exposure to toxins, prior chemotherapy or radiotherapy treatments, and the trend over time of blood count or lab findings.
Review of prior blood counts and lab work
The trend of the blood count over time is essential — a thrombocytopenia that has been stable for 6 months is different from one that is progressively declining. Bringing prior results to the consultation is important.
Protein electrophoresis when applicable
In patients with suspected monoclonal gammopathy, serum protein electrophoresis with immunofixation and free light chains is the initial screening study. It quantifies the M component and allows risk classification.
Peripheral blood morphology
The peripheral blood smear can identify cellular dysplasia, circulating blasts, or abnormal morphology not visible on the automated blood count.
Flow cytometry and immunophenotyping
In cytopenias of uncertain cause or persistent lymphocytosis, flow cytometry identifies clonal populations and allows classification of the affected cell type — essential for distinguishing benign from pre-malignant conditions.
Individualized surveillance plan
With the risk diagnosis established, the frequency of checkups, the studies to monitor, and the warning criteria that would indicate a shift from observation to treatment are defined.
Why consult Dr. Valvert for early diagnosis and prevention?
Dra. Fabiola Valvert
Hematologist specialized in Early Diagnosis and Prevention. Cutting-edge international training and private practice in Guatemala City.
Fellowship in flow cytometry and cytogenetics
The tools that allow detection of abnormal clones and pre-malignant states require specialized training. Dr. Valvert has a specific fellowship in flow cytometry and cytogenetics — the key technologies in early hematologic diagnosis.
Active research in hematologic diagnosis
Dr. Valvert has published in Blood Advances on molecular diagnosis of lymphomas in low- and middle-income countries, and participates in multicenter studies on hematologic epidemiology in Latin America. Her patients benefit from that ongoing update.
Up-to-date diagnostic criteria
Diagnostic and progression criteria for MGUS, smoldering myeloma, and myelodysplastic syndromes are updated periodically. Dr. Valvert applies the most recent WHO and International Myeloma Working Group criteria — not outdated classifications.
Continuous follow-up without interruptions
Active surveillance only works when it's continuous. Dr. Valvert designs the follow-up plan and carries it out — with scheduled checkups, results interpreted in context, and timely action on any significant change.
Do you have a hematologic diagnosis? Book your consultation today.
First visit, second opinion, or transplant consultation — all options available.
Specialized Hematology in Guatemala
Dra. Fabiola Valvert - Hematóloga
15 Avenida 5-50 zona 15 Vista Hermosa 3, Edificio Spazio, Oficina 10-01Bonanova, a private hospital specializing in cancer care in Zona 15
Office Hours
Monday to Friday from 9:00 AM to 6:00 PM Saturday from 9:00 AM to 12:00 PM
Emergency Care
Dr. Valvert handles hematologic emergencies through Bonanova, a private hospital specializing in cancer care with full infrastructure for urgent situations.
Coverage Areas
All of Guatemala City
- • Unrestricted care throughout the capital, including Zona 9, 10, 13, 14, 15, and 16
- • Carretera a El Salvador and surrounding areas
Metropolitan Area
- • Mixco, Villa Nueva, Santa Catarina Pinula, San Cristóbal, and surrounding municipalities
All of Guatemala
- • Care for patients from all departments of the country
- • Telehealth available for patients outside the capital
International Coverage
- • El Salvador, Belize, Honduras, and Costa Rica
- • Telehealth available for international patients
Common questions, clear answers
Still have questions? Let’s talk directly on WhatsApp for personalized answers.